1Beck, CA, Metz, LM, Svenson, LW, Patten, SB.Regional variation of multiple sclerosis prevalence in Canada. Mult Scler. 2005;11: 516–19.
2Murray, TJ.Diagnosis and treatment of multiple sclerosis. BMJ. 2006;332:525–7.
3Confavreux, C, Vukusic, S, Moreau, T, Adeleine, P.Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430–8.
4Beck, RW, Cleary, PA, Backlund, JC.The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthal. 1994;101:1771–8.
5Sellebjerg, F, Barnes, D, Filippini, G, et al.EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol. 2005;12:939–46.
6Goodin, DS, Frohman, EM, Garmany, GP Jr, et al.Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169–78.
7Metz, LM, Harris, CJ, Moore, A.MS patients’ choice of oral rather than IV steroid therapy results in savings to health care system. International Journal of MS Care (serial on the internet) 2000; March (cited 2010 Sept). Available at www.mscare.org
8Martinelli, V, Rocca, MA, Annovazzi, P, et al.A short-term randomized MRI study of high-dose oral vs. intravenous methylprednisolone in MS. Neurology. 2009;73:1842–8.
9Morrow, SA, Stoian, CA, Dmitrovic, J, Chan, SC, Metz, LM.The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology. 2004;63:1079–80.
10Burton, JM, O’Connor, PW, Hohol, M, Beyene, J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2009:CD006921.
11Metz, LM, Sabuda, D, Hilsden, RJ, Enns, R, Meddings, JB.Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology. 1999;53:2093–6.
12Beck, RW, Cleary, PA, Anderson, MM Jr., et al.A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581–8.
13Trobe, JD, Sieving, PC, Guire, KE, Fendrick, AM.The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology. 1999;106:2047–53.
14Tse, FL, Welling, PG.Relative bioavailability of prednisone and prednisolone in man. J Pharm Pharmacol. 1979;31:492–3.
15Morrow, SA, Metz, LM, Kremenchutzky, M.High dose oral steroids commonly used to treat relapses in Canadian MS clinics. Can J Neurol Sci. 2009;36:213–15.
16Goff, DC, Hill, M, Freudenreich, O.Treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2011;72:e13.
17Katon, WJ.Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 2011;13:7–23.
19Hohl, CM, Abu-Laban, RB, Brubacher, JR, et al.Adherence to emergency department discharge prescriptions. CJEM 2009;11: 131–8.
20Llor, C, Hernandez, S, Sierra, N, Moragas, A, Hernandez, M, Bayona, C.Association between use of rapid antigen detection tests and adherence to antibiotics in suspected streptococcal pharyngitis. Scand J Prim Health Care. 2010;28:12–17.